Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atreca Inc (BCEL)
OTHER OTC:BCEL
Atreca (BCEL) Stock Price & Analysis
463 Followers
BCEL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.05 - $1.26
Previous Close$0.09
Volume76.19K
Average Volume (3M)465.21K
Market Cap
$3.74M
Enterprise Value-$16.37M
Total Cash (Recent Filing)$21.39M
Total Debt (Recent Filing)$1.28M
Price to Earnings (P/E)>-0.1
Beta2.01
Next Earnings
Aug 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.49
Shares Outstanding39,624,075
10 Day Avg. Volume90,287
30 Day Avg. Volume465,212
Standard Deviation0.35
R-Squared0.02
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.33
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Atreca News
PremiumCompany Announcements
Atreca Inc Announces Executive Departures and Consulting Agreements
Bulls Say, Bears Say
Bulls Say
Financial HealthAtreca has cash and cash equivalents and investments totaling $21.4M.
Operational EfficiencyIn September, Atreca terminated its lease agreement of company headquarters which represents ~$13MM in annual savings.
Research And DevelopmentAPN-497444 binds a glycan and exhibits compelling pre-clinical anti-tumor activity and initial safety when weaponized as an ADC.
Bears Say
Company RestructuringAtreca announced a further 40% reduction in its workforce while maintaining support needed to explore strategic alternatives.
Cost Reduction StrategyBCEL announced plans to further reduce workforce by another 40% to conserve capital as strategic alternatives are explored.
Financial PerformanceAtreca reported a Q3 net loss of $36.2MM which includes ~$20MM in restructuring and impairment charges.
---
Ownership Overview
21.99% Insiders
3.76% Mutual Funds
16.41% Other Institutional Investors
57.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCEL FAQ
What was Atreca Inc’s price range in the past 12 months?
Atreca Inc lowest stock price was $0.05 and its highest was $1.26 in the past 12 months.
What is Atreca Inc’s market cap?
Currently, no data Available
When is Atreca Inc’s upcoming earnings report date?
Atreca Inc’s upcoming earnings report date is Aug 07, 2024 which is in 85 days.
How were Atreca Inc’s earnings last quarter?
Currently, no data Available
Is Atreca Inc overvalued?
According to Wall Street analysts Atreca Inc’s price is currently Overvalued.
Does Atreca Inc pay dividends?
Atreca Inc does not currently pay dividends.
What is Atreca Inc’s EPS estimate?
Atreca Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atreca Inc have?
Atreca Inc has 38,438,286 shares outstanding.
What happened to Atreca Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atreca Inc?
Among the largest hedge funds holding Atreca Inc’s share is Baker Bros Advisors LP. It holds Atreca Inc’s shares valued at 287K.
---
Atreca Stock Smart Score
Company Description
Atreca Inc
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.
---
BCEL Company Deck
---
BCEL Earnings Call
Q4 2023
0:00 / 0:00
---
BCEL Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Adaptimmune Therapeutics
―
Arvinas Holding Company
―
Arrowhead Pharmaceuticals
―
MacroGenics
―
Best Analysts Covering BCEL
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-46.09%
reiterated a buy rating 6 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -46.09% per trade.
---